How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration

Nature Structural Biology

Volumn 10, Issue 7, 2003, Pages 541-544

  Zhou, Aiwu ^a   Huntington, James A ^a   Pannu, Navraj S ^a,b   Carrell, Robin W ^a   Read, Randy J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; INTEGRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; SOMATOMEDIN B; VITRONECTIN;

ANGIOGENESIS; ARTICLE; CANCER; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CRYSTAL STRUCTURE; DRUG DESIGN; FIBRINOLYSIS; HEMOSTASIS; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; THROMBOSIS;

AMINO ACID SEQUENCE; CELL MOVEMENT; CRYSTALLIZATION; FIBRINOLYSIS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; RECOMBINANT PROTEINS; VITRONECTIN;

EID: 0037743532     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb943     Document Type: Article

References (33)

1. Preissner, K.T. et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor-1 with endothelial cell matrix-associated vitronectin. J. Biol. Chem. 265, 18490-18498 (1990).
2. Kohler, H.P. & Grant, P.J. Plasminogen activator inhibitor type 1 and coronary heart disease. N. Engl. J. Med. 342, 1792-1801 (2000).
3. McMahon, G.A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964-33968 (2001).
4. Devy, L. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16, 147-154 (2002).
5. Seiffert, D. & Loskutoff D.J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin domain of vitronectin. J. Biol. Chem. 266, 2824-2830 (1991).
6. 3 binding to vitronectin. Nature 383, 441-443 (1996).
7. Look, M.P. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94, 116-128 (2002).
8. Hekman, C.M. & Loskutoff, D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260, 11581-11587 (1985).
9. Mottonen, J. et al. Structural basis of latency in plasminogen-activator inhibitor-1. Nature 355, 270-273 (1992).
10. Lawrence, D.A. et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. J. Biol. Chem. 272, 7676-7680 (1997).
11. Schroeck, F., Arroyo de Prada, N., Sperl, S., Schmitt, M. & Magdolen, V. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol. Chem. 383, 1143-1149 (2002).
12. Okumura, Y. et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 277, 9395-9404 (2002).
13. Berkenpas, M.B., Lawrence, D.A. & Ginsburg, D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14, 2969-2977 (1995).
14. Lawrence, D.A., Berkenpas, M.B., Palaniappan, S., & Ginsburg, D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1, J. Biol. Chem. 269, 15223-15228 (1994).
15. Sigurdardottir, O. & Wiman, B. Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin. Fibrinolysis 6, 27-32 (1992).
16. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S. & Loskutoff, D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571 (1996).
17. 3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002).
18. Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928 (1998).
19. Harbeck, N. et al. Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor. Onkologie 24, 238-244 (2001).
20. Czekay, R.-P., Aertgeerts, K., Curriden, S.A. & Loskutoff, D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160, 781-791 (2003).
21. Gils, A. et al. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb. Haemost. 88, 137-143 (2002).
22. Yoneda, A., Ogawa, H., Kojima, K. & Matsumoto, I. Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry 37, 6351-6360 (1998).
23. Sharp, A.M. et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure Fold. Des. 7, 111-118 (1999).
24. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
25. Read, R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D 57, 1373-1382 (2001).
26. Read, R.J. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr. A 42, 140-149 (1986).
27. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
28. Winn, M.D., Isupov, M.N. & Murshudov, G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D 57, 122-133 (2001).
29. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
30. Laskowski, R.A., Moss, D.S. & Thornton, J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231, 1049-1067 (1993).
31. Kraulis, P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950 (1991).
32. Merritt, E.A. & Bacon, D.J. Raster3D photorealistic molecular graphics. Methods Enzymol. 277, 505-524 (1997).
33. Esnouf, R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15, 132-134 (1997).